Use your browser's back button to choose another title or click here for a New Search.



How to Get the Article

 Email CTN Library (free)

PubMed Central (free)

Download article (free)

 

 

Bookmark and Share

 

 

Association Between Hepatitis C Virus and Opioid Use While in Buprenorphine Treatment: Preliminary Findings.

American Journal of Drug and Alcohol Abuse 2014;41(1):88-92. [doi: 10.3109/00952990.2014.983274]

Sean M. Murphy, PhD (Washington State University, PN Node), Dana Dweik, MHPA (Cleveland Clinic Abu Dhabi), Sterling McPherson, PhD (Washington State University, PN Node), John M. Roll, PhD (Washington State University, PN Node).

The prevalence of hepatitis-C-virus (HCV) infections is high among opioid-dependent individuals. Prior research on the simultaneous treatment of both conditions has primarily assessed success as it pertains to HCV. However, it has been noted that favorable substance use therapy outcomes may improve the likelihood of HCV-treatment initiation and success. Therefore, current guidelines for the treatment of HCV among illicit drug users suggest that treatment for addiction be given the highest priority. This study aimed to determine whether opioid-dependent participants in a clinical trial of buprenorphine-treatment tapering regimens, who tested positive for the HCV antibody, experienced significantly different levels of opioid abstinence than those not infected. Data came from the National Drug Abuse Treatment Clinical Trials Network study CTN-0003, which compared two taper schedules for buprenorphine-naloxone (one rapid and one gradual, n=516). Participants with the HCV antibody were significantly less likely to submit opioid-negative urine analyses during and/or immediately following active treatment, indicating a higher rate of opioid use among this group.

Conclusions: Individualized opioid-dependence treatment strategies may be required for opioid-dependent individuals who test positive for the HCV antibody in order to ensure resources for both opioid-dependence and HCV therapies are used efficiently. (Article (Peer-Reviewed), PDF, English, 2014)

Keywords: Buprenorphine/Naloxone | CTN platform/ancillary study | Hepatitis C | Heroin | Injection drug use | Opioid dependence | Prescription-type opiates | Sexually transmitted diseases | Suboxone | Taper schedules | American Journal of Drug and Alcohol Abuse (journal)

Document No: 1111, PMID: 25490610, PMCID: PMC4638227.

Submitted by the CTN Dissemination Librarians, 12/15/2014.

AUTHORS SEARCH LINK
Dweik, Dana search
McPherson, Sterling search mail
Murphy, Sean M. search mail
Roll, John M. search mail
PROTOCOLS
NIDA-CTN-0003 search www

Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 11/2015 -- http://ctndisseminationlibrary.org/display/1111.htm
info@ctndisseminationlibrary.org